Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Intraductal, Noninfiltrating | 21 | 2023 | 947 | 5.600 |
Why?
|
Breast Neoplasms | 63 | 2023 | 20774 | 3.460 |
Why?
|
Carcinoma, Ductal, Breast | 11 | 2021 | 1101 | 3.240 |
Why?
|
Mastectomy, Segmental | 23 | 2021 | 955 | 2.830 |
Why?
|
Neoplasm Recurrence, Local | 25 | 2020 | 9185 | 2.170 |
Why?
|
Radiotherapy, Adjuvant | 15 | 2022 | 1769 | 1.590 |
Why?
|
Decision Support Techniques | 15 | 2020 | 1952 | 1.530 |
Why?
|
Carcinoma in Situ | 3 | 2021 | 802 | 1.360 |
Why?
|
Mastectomy | 15 | 2022 | 1789 | 1.340 |
Why?
|
Markov Chains | 17 | 2020 | 969 | 1.300 |
Why?
|
Radiosurgery | 5 | 2016 | 1309 | 1.230 |
Why?
|
Tamoxifen | 7 | 2023 | 980 | 1.190 |
Why?
|
Receptors, Estrogen | 9 | 2020 | 2186 | 1.090 |
Why?
|
Antineoplastic Agents, Hormonal | 7 | 2013 | 1509 | 0.980 |
Why?
|
Receptors, Progesterone | 5 | 2020 | 1097 | 0.960 |
Why?
|
SEER Program | 15 | 2022 | 1507 | 0.930 |
Why?
|
Quality-Adjusted Life Years | 9 | 2018 | 1679 | 0.830 |
Why?
|
Radiotherapy, Intensity-Modulated | 4 | 2018 | 806 | 0.790 |
Why?
|
Combined Modality Therapy | 20 | 2021 | 8621 | 0.750 |
Why?
|
Neoplasm Staging | 23 | 2021 | 11001 | 0.700 |
Why?
|
Aromatase Inhibitors | 3 | 2008 | 491 | 0.650 |
Why?
|
Chemotherapy, Adjuvant | 9 | 2020 | 3471 | 0.610 |
Why?
|
Decision Making | 4 | 2021 | 3869 | 0.610 |
Why?
|
Cost-Benefit Analysis | 12 | 2020 | 5385 | 0.550 |
Why?
|
Prostate-Specific Antigen | 4 | 2007 | 2458 | 0.540 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 4 | 2016 | 5171 | 0.530 |
Why?
|
Patient Participation | 2 | 2015 | 1445 | 0.510 |
Why?
|
Receptor, erbB-2 | 5 | 2022 | 2410 | 0.480 |
Why?
|
Mastectomy, Modified Radical | 1 | 2013 | 62 | 0.450 |
Why?
|
Cranial Irradiation | 1 | 2016 | 401 | 0.450 |
Why?
|
Female | 73 | 2023 | 379592 | 0.440 |
Why?
|
Aged | 54 | 2022 | 162944 | 0.430 |
Why?
|
Secondary Prevention | 2 | 2023 | 1520 | 0.430 |
Why?
|
Oropharyngeal Neoplasms | 1 | 2018 | 475 | 0.430 |
Why?
|
Lymph Node Excision | 4 | 2014 | 1248 | 0.420 |
Why?
|
Cytochrome P-450 CYP2D6 | 2 | 2013 | 106 | 0.420 |
Why?
|
Neoplasms, Second Primary | 2 | 2018 | 1052 | 0.420 |
Why?
|
Patient Preference | 1 | 2019 | 886 | 0.420 |
Why?
|
Middle Aged | 55 | 2021 | 213127 | 0.410 |
Why?
|
Comparative Effectiveness Research | 2 | 2014 | 681 | 0.400 |
Why?
|
Quality of Life | 5 | 2020 | 12730 | 0.390 |
Why?
|
Carcinoma, Lobular | 3 | 2022 | 484 | 0.380 |
Why?
|
Radiation Oncology | 4 | 2023 | 554 | 0.370 |
Why?
|
Models, Economic | 2 | 2017 | 713 | 0.370 |
Why?
|
Humans | 90 | 2023 | 742088 | 0.360 |
Why?
|
Prostatic Neoplasms | 6 | 2018 | 11039 | 0.350 |
Why?
|
Radiotherapy | 6 | 2020 | 1525 | 0.350 |
Why?
|
Disease-Free Survival | 9 | 2015 | 6891 | 0.350 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2018 | 4029 | 0.330 |
Why?
|
Aged, 80 and over | 29 | 2019 | 57683 | 0.320 |
Why?
|
Tumor Burden | 5 | 2018 | 1905 | 0.320 |
Why?
|
Estrogen Receptor Modulators | 1 | 2008 | 61 | 0.320 |
Why?
|
Neck Dissection | 1 | 2009 | 196 | 0.320 |
Why?
|
Lung Neoplasms | 5 | 2019 | 13019 | 0.310 |
Why?
|
Neoplasm Invasiveness | 6 | 2018 | 3612 | 0.290 |
Why?
|
Brain Neoplasms | 4 | 2017 | 8829 | 0.290 |
Why?
|
Brachytherapy | 2 | 2011 | 1246 | 0.280 |
Why?
|
Survival Analysis | 8 | 2019 | 10248 | 0.270 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 11472 | 0.270 |
Why?
|
Postmenopause | 4 | 2008 | 2461 | 0.270 |
Why?
|
Computer Simulation | 4 | 2018 | 6191 | 0.260 |
Why?
|
Adult | 39 | 2021 | 213712 | 0.260 |
Why?
|
Insurance, Liability | 2 | 2017 | 102 | 0.260 |
Why?
|
Survivors | 3 | 2010 | 2286 | 0.260 |
Why?
|
Lymphatic Metastasis | 7 | 2018 | 2906 | 0.260 |
Why?
|
Mammaplasty | 3 | 2022 | 1195 | 0.250 |
Why?
|
Guideline Adherence | 2 | 2011 | 2266 | 0.240 |
Why?
|
Treatment Outcome | 15 | 2020 | 62966 | 0.230 |
Why?
|
Prognosis | 12 | 2020 | 29010 | 0.230 |
Why?
|
Age Factors | 9 | 2018 | 18355 | 0.230 |
Why?
|
Follow-Up Studies | 13 | 2020 | 39004 | 0.230 |
Why?
|
Estrogen Antagonists | 1 | 2003 | 151 | 0.220 |
Why?
|
Postoperative Period | 2 | 2016 | 1839 | 0.220 |
Why?
|
Healthcare Disparities | 3 | 2022 | 3151 | 0.210 |
Why?
|
Prostatic Hyperplasia | 1 | 2006 | 522 | 0.200 |
Why?
|
Stomach Neoplasms | 1 | 2011 | 1327 | 0.200 |
Why?
|
Radiotherapy Dosage | 6 | 2015 | 2876 | 0.200 |
Why?
|
Sentinel Lymph Node Biopsy | 3 | 2018 | 701 | 0.200 |
Why?
|
Selection Bias | 1 | 2003 | 369 | 0.200 |
Why?
|
Malpractice | 2 | 2017 | 569 | 0.190 |
Why?
|
Breast | 2 | 2022 | 1958 | 0.190 |
Why?
|
Logistic Models | 8 | 2017 | 13403 | 0.180 |
Why?
|
United States | 14 | 2023 | 69693 | 0.170 |
Why?
|
Depression | 1 | 2018 | 7733 | 0.170 |
Why?
|
Propensity Score | 2 | 2016 | 1771 | 0.170 |
Why?
|
Health Care Costs | 2 | 2011 | 3203 | 0.170 |
Why?
|
Prostate | 2 | 2005 | 1764 | 0.160 |
Why?
|
Dysgeusia | 1 | 2018 | 14 | 0.160 |
Why?
|
Odds Ratio | 6 | 2017 | 9846 | 0.160 |
Why?
|
Research Design | 1 | 2014 | 5979 | 0.150 |
Why?
|
Xerostomia | 1 | 2018 | 95 | 0.150 |
Why?
|
Axilla | 3 | 2018 | 588 | 0.150 |
Why?
|
Mass Screening | 2 | 2010 | 5238 | 0.150 |
Why?
|
Catheter Ablation | 1 | 2011 | 2746 | 0.150 |
Why?
|
Carboplatin | 1 | 2020 | 799 | 0.140 |
Why?
|
Breast Implantation | 1 | 2019 | 218 | 0.140 |
Why?
|
Neoplasm, Residual | 3 | 2017 | 974 | 0.140 |
Why?
|
Risk | 3 | 2019 | 9679 | 0.140 |
Why?
|
Sensitivity and Specificity | 5 | 2018 | 14720 | 0.130 |
Why?
|
Head and Neck Neoplasms | 1 | 2009 | 2712 | 0.130 |
Why?
|
Gastrostomy | 1 | 2018 | 309 | 0.130 |
Why?
|
Frozen Sections | 1 | 2016 | 155 | 0.130 |
Why?
|
Retrospective Studies | 12 | 2022 | 77098 | 0.130 |
Why?
|
Lymphedema | 1 | 2002 | 528 | 0.130 |
Why?
|
Endothelial Growth Factors | 1 | 1997 | 694 | 0.130 |
Why?
|
Cisplatin | 1 | 2021 | 1637 | 0.130 |
Why?
|
Survival Rate | 6 | 2018 | 12773 | 0.120 |
Why?
|
Doxorubicin | 2 | 2020 | 2215 | 0.120 |
Why?
|
Time Factors | 8 | 2017 | 40054 | 0.120 |
Why?
|
Chemoprevention | 1 | 2017 | 319 | 0.120 |
Why?
|
Lymphokines | 1 | 1997 | 949 | 0.120 |
Why?
|
Carcinoma | 1 | 2006 | 2374 | 0.120 |
Why?
|
Cyclophosphamide | 1 | 2020 | 2236 | 0.120 |
Why?
|
Risk Assessment | 4 | 2018 | 23320 | 0.120 |
Why?
|
Adenocarcinoma | 1 | 2011 | 6347 | 0.110 |
Why?
|
Positron-Emission Tomography | 1 | 2009 | 6259 | 0.110 |
Why?
|
Mammography | 3 | 2018 | 2474 | 0.110 |
Why?
|
Watchful Waiting | 1 | 2017 | 491 | 0.110 |
Why?
|
Medicare | 3 | 2022 | 6532 | 0.110 |
Why?
|
Fear | 1 | 2021 | 1436 | 0.110 |
Why?
|
Extremities | 1 | 2017 | 865 | 0.100 |
Why?
|
Reoperation | 3 | 2017 | 4200 | 0.100 |
Why?
|
Multivariate Analysis | 4 | 2011 | 12242 | 0.100 |
Why?
|
Radiation Injuries | 2 | 2017 | 1178 | 0.100 |
Why?
|
Withholding Treatment | 1 | 2015 | 598 | 0.100 |
Why?
|
Neoplasm Metastasis | 3 | 2015 | 4839 | 0.100 |
Why?
|
Male | 18 | 2020 | 349538 | 0.090 |
Why?
|
Tomography, X-Ray Computed | 4 | 2015 | 20086 | 0.090 |
Why?
|
Cohort Studies | 6 | 2022 | 40450 | 0.090 |
Why?
|
Utilization Review | 1 | 2011 | 392 | 0.090 |
Why?
|
Residence Characteristics | 1 | 2020 | 2049 | 0.090 |
Why?
|
Hodgkin Disease | 2 | 2009 | 1413 | 0.090 |
Why?
|
Patient-Centered Care | 1 | 2020 | 1436 | 0.090 |
Why?
|
Insulin-Like Growth Factor I | 1 | 1997 | 2014 | 0.090 |
Why?
|
Biopsy | 3 | 2007 | 6756 | 0.090 |
Why?
|
Risk Factors | 6 | 2018 | 72145 | 0.080 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 2 | 2015 | 1622 | 0.080 |
Why?
|
Neoadjuvant Therapy | 1 | 2020 | 2721 | 0.080 |
Why?
|
Health Services Accessibility | 1 | 2006 | 5133 | 0.080 |
Why?
|
Monte Carlo Method | 1 | 2014 | 1254 | 0.080 |
Why?
|
Practice Guidelines as Topic | 3 | 2011 | 7276 | 0.080 |
Why?
|
Medical Errors | 1 | 2017 | 1296 | 0.080 |
Why?
|
Lymph Nodes | 3 | 2016 | 3465 | 0.080 |
Why?
|
Xanthenes | 1 | 2007 | 73 | 0.080 |
Why?
|
Disease Progression | 3 | 2018 | 13256 | 0.080 |
Why?
|
Analysis of Variance | 3 | 2011 | 6365 | 0.080 |
Why?
|
Urinary Bladder | 1 | 2014 | 1171 | 0.080 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2008 | 129 | 0.080 |
Why?
|
Drug Administration Schedule | 2 | 2006 | 4929 | 0.080 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2018 | 1631 | 0.080 |
Why?
|
Insurance, Health | 1 | 2020 | 2493 | 0.080 |
Why?
|
Radiotherapy, Conformal | 1 | 2011 | 548 | 0.080 |
Why?
|
Seminoma | 1 | 2008 | 136 | 0.070 |
Why?
|
Prospective Studies | 7 | 2021 | 53187 | 0.070 |
Why?
|
Patient Satisfaction | 1 | 2019 | 3391 | 0.070 |
Why?
|
ROC Curve | 2 | 2005 | 3528 | 0.070 |
Why?
|
Models, Statistical | 3 | 2018 | 5100 | 0.070 |
Why?
|
Gastrectomy | 1 | 2011 | 652 | 0.070 |
Why?
|
Antineoplastic Agents | 3 | 2017 | 13655 | 0.070 |
Why?
|
Terminology as Topic | 1 | 2013 | 1548 | 0.070 |
Why?
|
Papillomavirus Infections | 1 | 2018 | 1585 | 0.070 |
Why?
|
Primary Prevention | 1 | 2013 | 1166 | 0.070 |
Why?
|
Frail Elderly | 1 | 2011 | 691 | 0.070 |
Why?
|
Neoplasms | 2 | 2017 | 21596 | 0.070 |
Why?
|
Postoperative Complications | 2 | 2012 | 15244 | 0.070 |
Why?
|
Sarcoma | 1 | 2017 | 1895 | 0.070 |
Why?
|
Patient Education as Topic | 1 | 2015 | 2275 | 0.070 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2008 | 414 | 0.060 |
Why?
|
Clinical Trials as Topic | 2 | 2013 | 7901 | 0.060 |
Why?
|
Pain Measurement | 1 | 2014 | 3418 | 0.060 |
Why?
|
Predictive Value of Tests | 3 | 2010 | 15056 | 0.060 |
Why?
|
Proportional Hazards Models | 3 | 2018 | 12344 | 0.060 |
Why?
|
Gene Expression Profiling | 1 | 2020 | 9410 | 0.060 |
Why?
|
Mortality | 1 | 2015 | 2857 | 0.060 |
Why?
|
Cancer Care Facilities | 1 | 2006 | 401 | 0.060 |
Why?
|
Young Adult | 7 | 2021 | 56350 | 0.060 |
Why?
|
Databases, Factual | 2 | 2015 | 7716 | 0.060 |
Why?
|
Internet | 1 | 2015 | 3062 | 0.060 |
Why?
|
Magnetic Resonance Imaging | 1 | 2010 | 35342 | 0.060 |
Why?
|
Genomics | 1 | 2018 | 5692 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2018 | 8425 | 0.050 |
Why?
|
Nitriles | 1 | 2007 | 952 | 0.050 |
Why?
|
Testicular Neoplasms | 1 | 2008 | 761 | 0.050 |
Why?
|
Heart | 1 | 2015 | 4462 | 0.050 |
Why?
|
Imaging, Three-Dimensional | 1 | 2015 | 4029 | 0.050 |
Why?
|
Depressive Disorder, Major | 1 | 2019 | 4628 | 0.050 |
Why?
|
Socioeconomic Factors | 2 | 2012 | 7770 | 0.050 |
Why?
|
Reproducibility of Results | 3 | 2009 | 19862 | 0.050 |
Why?
|
Pancreatic Neoplasms | 1 | 2018 | 5249 | 0.050 |
Why?
|
Cross-Over Studies | 1 | 2006 | 2030 | 0.050 |
Why?
|
Registries | 2 | 2012 | 8077 | 0.040 |
Why?
|
Incidence | 2 | 2017 | 20928 | 0.040 |
Why?
|
Gene Expression Regulation | 1 | 1997 | 12071 | 0.040 |
Why?
|
Reference Values | 1 | 2006 | 4982 | 0.040 |
Why?
|
Maximum Tolerated Dose | 1 | 2021 | 891 | 0.040 |
Why?
|
Physicians | 1 | 2017 | 4554 | 0.040 |
Why?
|
Lipids | 1 | 2009 | 3302 | 0.040 |
Why?
|
Tissue Expansion Devices | 1 | 2019 | 156 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2013 | 12958 | 0.040 |
Why?
|
Disease Management | 2 | 2019 | 2450 | 0.040 |
Why?
|
Genotype | 2 | 2013 | 12946 | 0.040 |
Why?
|
Pigment Epithelium of Eye | 1 | 1997 | 220 | 0.040 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2018 | 281 | 0.040 |
Why?
|
Lung | 1 | 2015 | 9826 | 0.040 |
Why?
|
Epidemiologic Factors | 1 | 2015 | 30 | 0.030 |
Why?
|
Culture Media, Conditioned | 1 | 1997 | 533 | 0.030 |
Why?
|
Cell Line, Transformed | 1 | 1997 | 898 | 0.030 |
Why?
|
Life Expectancy | 2 | 2017 | 1183 | 0.030 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 1997 | 772 | 0.030 |
Why?
|
Blotting, Northern | 1 | 1997 | 1581 | 0.030 |
Why?
|
Population Surveillance | 1 | 2006 | 2616 | 0.030 |
Why?
|
Reactive Oxygen Species | 1 | 2023 | 2077 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 2 | 2018 | 6534 | 0.030 |
Why?
|
Receptor, IGF Type 1 | 1 | 1997 | 390 | 0.030 |
Why?
|
Inhalation | 1 | 2015 | 143 | 0.030 |
Why?
|
Decision Trees | 1 | 2017 | 506 | 0.030 |
Why?
|
Intraoperative Period | 1 | 2016 | 520 | 0.030 |
Why?
|
Cell Hypoxia | 1 | 1997 | 675 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2014 | 9941 | 0.030 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2022 | 1683 | 0.030 |
Why?
|
Lymphatic Irradiation | 1 | 2014 | 104 | 0.030 |
Why?
|
Capillaries | 1 | 1997 | 774 | 0.030 |
Why?
|
Models, Theoretical | 1 | 2006 | 3584 | 0.030 |
Why?
|
Organs at Risk | 1 | 2015 | 346 | 0.030 |
Why?
|
Factor Analysis, Statistical | 1 | 2015 | 975 | 0.030 |
Why?
|
Adolescent | 4 | 2017 | 85649 | 0.030 |
Why?
|
Income | 1 | 2020 | 1904 | 0.020 |
Why?
|
Mutation | 2 | 2022 | 29717 | 0.020 |
Why?
|
Thoracic Wall | 1 | 2012 | 201 | 0.020 |
Why?
|
Recurrence | 1 | 2022 | 8333 | 0.020 |
Why?
|
Cell Division | 1 | 1997 | 4564 | 0.020 |
Why?
|
Sex Distribution | 1 | 2015 | 2295 | 0.020 |
Why?
|
Kinetics | 1 | 1997 | 6474 | 0.020 |
Why?
|
Brain | 1 | 2016 | 26343 | 0.020 |
Why?
|
Antibodies | 1 | 1997 | 2459 | 0.020 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 1183 | 0.020 |
Why?
|
Salvage Therapy | 1 | 2015 | 1269 | 0.020 |
Why?
|
Urban Population | 1 | 2016 | 2018 | 0.020 |
Why?
|
Analgesics | 1 | 2014 | 1037 | 0.020 |
Why?
|
Medicine | 1 | 2015 | 941 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 1997 | 3502 | 0.020 |
Why?
|
Orchiectomy | 1 | 2008 | 466 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 1997 | 5867 | 0.020 |
Why?
|
Rural Population | 1 | 2016 | 2207 | 0.020 |
Why?
|
Bleomycin | 1 | 2006 | 499 | 0.020 |
Why?
|
Reimbursement Mechanisms | 1 | 2011 | 670 | 0.020 |
Why?
|
Endothelium, Vascular | 1 | 1997 | 4455 | 0.020 |
Why?
|
Activities of Daily Living | 1 | 2014 | 2414 | 0.020 |
Why?
|
Vinblastine | 1 | 2006 | 490 | 0.020 |
Why?
|
Linear Models | 1 | 2015 | 5948 | 0.020 |
Why?
|
Regression Analysis | 1 | 2014 | 6452 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2022 | 21719 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2015 | 24913 | 0.010 |
Why?
|
Dacarbazine | 1 | 2006 | 567 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8328 | 0.010 |
Why?
|
RNA, Messenger | 1 | 1997 | 13029 | 0.010 |
Why?
|
Comorbidity | 1 | 2015 | 10372 | 0.010 |
Why?
|
Observer Variation | 1 | 2007 | 2593 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2011 | 3691 | 0.010 |
Why?
|
Mice | 1 | 1997 | 81045 | 0.010 |
Why?
|
Animals | 1 | 1997 | 168561 | 0.000 |
Why?
|